Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and inflammatory conditions, using novel targets and improved modalities.
Cancer therapy has evolved from potent chemotherapy to targeted biological therapy, including ADCs. Learn more about ADCs’ makeup, mechanisms, and the development landscape.
In 2025, AI-powered adaptive protocols will redefine study design, shifting the industry from rigid, pre-planned models to flexible, real-world-optimized trials.
By 2025 and beyond, AI, structured data, and real-world evidence will reshape the landscape, driving personalized medicine and more efficient processes. Here are eight key trends to watch.
This website uses cookies to ensure you get the best experience on our website. Learn more
